6 February 2018

RCT demonstrates that patients treated with Leaf Patient Monitoring System are 73% less likely to develop a pressure injury

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announces that researchers at Stanford Health Care have found that patients treated with Leaf, a wireless device that is adhered to a patient's chest to monitor the patient's position, orientation, movement and activity, are 73% less likely to develop a pressure injury.1

The investigator-initiated randomized control trial (RCT) involved more than 1,200 patients and over 100,000 hours of data was analysed. The Leaf sensor was used to help ensure that patients were repositioned with sufficient frequency and quality. The optimized care delivery enabled by Leaf resulted in a significant reduction in hospital acquired pressure injuries.

Pressure injuries are among the most common and costly hospital-acquired conditions, costing the US healthcare system $11 billion annually.2 The cost to treat pressure ulcers/injuries across the episode of a wound can be over $70,000 for a full-thickness wound.3

“This large randomized controlled trial confirms what has been demonstrated in smaller studies and is consistent with real-world customer experience,” said Leaf Healthcare CEO and co-founder Barrett Larson. “This study is an important step towards redefining the standard of care for pressure injury prevention.”

The Leaf System is exclusively distributed by Smith & Nephew, also an investor in the company. Mike Zagger, SVP US Wound Management, Smith & Nephew, commented, “This study confirms that the optimized care delivery enabled by Leaf is translated into a significant reduction in hospital-acquired pressure injuries. We are proud to provide this device, alongside our full suite of pioneering products, to support healthcare professionals and enable them to reduce the human and economic cost of wounds.”

For detailed product information, please consult product’s Instructions for Use (IFU) prior to use.

To learn more about what we do to help reduce pressure ulcer incidence, please visit www.closertozero.com

Enquiries

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew

Investors / Analysts

Ingeborg Øie
+44 (0)20 7960 2285
Smith & Nephew

About Leaf Healthcare, Inc.

Leaf Healthcare creates wireless patient monitoring solutions for healthcare providers seeking efficient, cost effective ways to improve patient safety and clinical outcomes. Its patient monitoring system wirelessly monitors patient position and movement and uses that data to improve patient safety, clinical efficiency, and patient outcomes. To learn more, visit www.leafhealthcare.com

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

References

1.Pickham, D. et al. Effect of a wearable patient sensor on care delivery for preventing pressure injuries in acutely ill adults: A pragmatic randomized clinical trial (LS-HAPI study). International Journal of Nursing Studies 80 (2018) 12-19. https://www.ncbi.nlm.nih.gov/pubmed/29331656.

2.Russo et al. Hospitalizations Related to Pressure Ulcers, 2006. HCUP Statistical Brief #64. December 2008. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb64.pdf.

3. Reddy et al. Preventing Pressure Ulcers: A Systematic Review. JAMA, August 23/30 2006 Vol 296, No 8 (Reprinted)

 

Title

Text